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Background: Hyperechogenicity of the substantia nigra (SN) measured by trans-
cranial sonography (TCS) is a characteristic feature observed in patients with 
Parkinson’s disease (PD). To our knowledge, no SN hyperechogenicity data are 
available for Polish population. Moreover most of studies come from few centres, 
which used the one type of ultrasound device. The main aim of the study was to 
investigate the association between PD and SN hyperechogenicity measured by 
sonographic machine, not assessed so far. 
Materials and methods: In this study cross-sectional study SN hyperechogenicity 
was evaluated in 102 PD patients and 95 control subjects. Midbrain was visuali-
sed by Aloka Prosound 7 ultrasound device. SN area measurement, the relation 
to the clinical features of PD, inter- and intra-observer reliability were evaluated. 
Results: We confirmed that SN echogenicity is significantly increased in PD patients 
compared to control subjects (p < 0.001). The area under curve for PD patients 
vs. controls was 0.93. Receiver operating characteristic analysis indicated a cut-offs 
for SN echogenicity at 0.19 cm2 with accuracy equal to 90%, specificity — 86% 
and sensitivity — 93.7%. The SN hyperechogenicity was not related to PD clinical 
findings. Reliability was good if an experienced sonographer performed the SN 
measurements.
Conclusions: This study shows that the SN abnormality observed by TCS is 
a specific feature, which can be helpful in the process of PD diagnosing. (Folia 
Morphol 2014; 73, 3: 267–271)
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INTRODUCTION
Parkinson’s disease (PD) is one of the most frequ-
ent neurological conditions [13, 23] and some proved 
that it is the second most common neurodegenerative 
disorder [15]. Despite the seriousness of the issue the 
one specific test which might help to put final diag-
nose has not been established; dopamine transporter 
single photon emission computed tomography brain 
imaging (DaT-SPECT) which could be useful in the 
assessment of parkinsonism with nigrostratial dege-
neration is expensive and not widely available. In the 
routine practice the clinical symptoms and criteria still 
decide about the diagnosis of the disease. 
Transcranial brain sonography (TCS) is a relatively 
new imaging technique that can reveal selected stru-
ctures of the brain parenchyma. Several years ago 
changes of the substantia nigra (SN) echogenicity in 
TCS in PD patients were revealed [2]. Recently many 
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studies have confirmed that SN hyperechogenicity 
(Fig. 1) is distinguishing feature of PD [4, 25, 32], 
moreover some of them have shown that this pheno-
menon is observed in about 90% of PD cases [11, 20]: 
it seems that this non-invasive and low-cost imaging 
technique, may be valuable in PD diagnosing process. 
However we should emphasize that large observa-
tions have been done on one type of the ultrasound 
system (Siemens Sonoline, Germany) and experts in 
the field claim that every laboratory should establish 
its own specific reference values for SN echogenicity 
measurements [6, 29].
To our knowledge, the SN hyperechogenicity vi-
sualised by TCS have not been assessed in Polish 
population. 
The aim of our study was to analyse this sono-
graphic phenomenon in the Polish PD population 
and control subjects using a different (until now 
not evaluated) ultrasound device (Aloka Prosound, 
Japan). In this trial the relation of the sonographic 
findings to the clinical features of PD patients was 
also evaluated. Additionally inter- and intra-observer 
reliability was calculated. 
MATERIALS AND METHODS
In this cross-sectional, case-control study 102 
consecutive patients with sporadic type of PD ho-
spitalised between August, 2011 and April, 2013 at 
the Neurology Department in the university hospital 
in Poznan (Poland) have been included. The local 
Ethics Committee of the Poznan University of Medical 
Sciences approved the protocol of the study. 
 The PD was diagnosed in the agreement with 
given criteria, which consist of the presence of 3 (pro-
bable PD) of the 4 cardinal features (resting tremor, 
bradykinesia, rigidity, asymmetric onset), and with 
significant reaction to conventional therapy (L-dopa 
or a dopamine agonist) [16]. All patients underwent 
magnetic resonance imaging in order to exclude 
symptomatic parkinsonism. None of the PD cases 
has recognisable cause of secondary parkinsonism 
or presented atypical symptoms such as pyramidal 
signs, gaze palsy or cerebellar ataxia. 
The control group consisted of 95 patients wit-
hout any central nervous disease. They were con-
secutively hospitalised because of musculoskeletal 
disorders and polyneuropathies. 
All subjects underwent comprehensive clinical 
and TCS examination, which were performed inde-
pendently by physicians blinded to the results of the 
other investigation. To assess the disease severity, 
the PD patients were examined using the Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) and 
Hoehn and Yahr stage grading [17, 19]. The categori-
sation of the patients with regard to their motor symp-
toms was performed using given criteria according to 
UPDRS III items specific for bradykinesia, rigidity and 
tremor. Patients were considered to have a tremor-
-dominant type (TD) if their symptom score achieved 
3 points in tremor items, and score 0 or 1 in bradyki-
nesia and rigidity items. The subjects were classified to 
have an akinetic-rigid type (AR) if their symptom score 
was 3 points in 3 bradykinesia and rigidity items, and 
a score of 0 or 1 in tremor items. The mixed type 
has been chosen if patients had another combination of 
scores specific for bradykinesia, rigidity, and tremor [22].
TCS examination was performed as described in 
experts’ recommendations and review article [1, 30]. 
Figure 1. Ultrasound image of midbrain with; A. Substantia nigra (SN) in control subject; B. SN in Parkinson’s disease patient (circled by white line).
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Briefly, an ultrasound device with a phased array 
2.5–3.5 MHz transducer (Aloka Prosound, Japan), 
the penetration depth 14–16 cm, automatic adjusted 
gain compensation and brightness and examined 
scanning plane through the temporal acoustic bone 
window have been used. On the optimal images of 
the butterfly-shaped hypoechogenic midbrain surro-
unded by hyperechogenic basal cisterns we manually 
encircled the echogenic area corresponding to the SN. 
An expert sonographer examined all subjects and he 
performed measurements twice offline. Additionally, 
experienced sonographer but with only basic skills in 
the TCS repeated measurements in randomly selected 
30 PD patients and 30 control subjects. Thus intra-
-rater and inter-rater reliability could be estimated. 
Statistical analyses
Descriptive statistics are given as mean and stan-
dard deviation (SD). Normal distribution of data 
was assessed by Shapiro-Wilk test. In the statistical 
analysis, nonparametric test (Mann-Whitney U test), 
parametric unpaired t test, Fisher’s exact test have 
been applied. Receiver operating characteristics (ROC) 
were performed to assess the accuracy of TCS for 
differentiation of PD patients and control subjects.
For inter-rater and intra-rater correlation, intra-
-class correlation coefficients (ICC, two-way random 
model, absolute agreement) for SN hyperechogenicity 
measurements were determined. Reliability values 
were classified as: 0.00–0.10 — none; 0.11–0.40 — 
slight; 0.41–0.60 — fair; 0.61–0.80 — moderate; 
0.81–1.00 — substantial [27].
Differences were assumed to be significant at 
p < 0.05. Statistical evaluations were conducted using 
MedCalc Software (version 12.7.2, Ostend, Belgium).
RESULTS
Seven (7%) subjects were excluded from the study 
PD group due to an insufficient temporal bone win-
dow. Final statistical analysis included 95 PD patients 
and 95 controls. There was no significant difference 
in sex and age between the groups. 
The mean area of SN hyperechogenicity was signi-
ficantly greater in the PD patients than in the controls 
0.23 ± 0.04 cm2 and 0.12 ± 0.06 cm2, respectively, 
p < 0.001 (Fig. 2). 
ROC of SN echogenicity showed an area under 
the curve of 0.93 (95% confidence interval [CI], 0.89– 
–0.96) for differentiation of PD patients and control 
subjects. Analysis of ROC indicated a cut-off for SN 
Figure 3. Receiver operating characteristic curve for discrimination 
of Parkinson’s disease patients (n = 95) and control subjects (n = 95) 
by sonographic measurement of substantia nigra echogenicity; for 
cut-off value = 0.19 cm2, sensitivity is 93.7% and specificity is 86%.
Figure 2. Area of substantia nigra (SN) hyperechogenicity in 
Parkinson’s disease (PD) patients and control subjects (box plots 
show mean with standard deviation values). 
echogenicity at 0.19 cm2 (Fig. 3). For this cut off 
accuracy was 90%, specificity was 86%, sensitivity 
was 93.7%, the positive predictive value was 85.7% 
and the negative predictive value was 82.8%. Seventy 
eight (82%) of PD patients and 10 (10%) of control 
subject had SN echogenicity above cut-off value i.e. 
> 0.19 cm2.  
The intra-observer ICC value for experienced sono-
grapher was very good — 0.94 (95% CI 0.86–0.97), 
for physician with basic skills in the TCS was moderate 
— 0,79 (95% CI 0.58–0.9). Inter-observer ICC value 
was moderate as well — 0.7 (95% CI 0.43–0.86).
Table 1 shows clinical data after cut-off value 
usage to separate PD subjects with SN ≤ 0.19 cm2 
and SN > 0.19 cm2. There was no difference between 
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subgroups in age, sex, disease duration, as well as 
MDS-USRS and Hoehn and Yahr stages of disease.
There was no statistically significant difference 
in the SN echogenic area between the TD, AR, and 
mixed type PD patients.
DISCUSSION 
Consistent with number of previous reports from 
independent centres [14, 20, 21, 25, 28] our study 
confirmed a morphological abnormality of the SN vi-
sualised by TCS in the majority of PD patients. It is the 
first trial that investigated the size of SN hyperecho-
genic area in a large group of Polish population. We 
defined SN > 0.19 cm2 as an abnormal extension of 
hyperechogenicity with the sensitivity is 86.3%, spe-
cificity 94%, with positive predictive value of 85.7%, 
and negative predictive value of 82.8%. 
This study showed that SN hyperechogenicity in 
PD patients was not correlated with age, disease 
duration, Hoehn and Yahr staging or the unified PD 
rating scale motor symptoms, disease severity, that 
harmonised with most of the previous reports [25, 
31]. We also confirmed earlier findings that the SN 
hyperechogenicity is not different among the motor 
subcategories of PD [11]. Therefore, all these data 
may suggest that structural changes revealed in TCS 
do not determine severity of PD symptoms.
We have also noticed that 10% of control subject 
had this ultrasound phenomenon, which lies within 
formerly reported 8–10% range.
Recent results of several longitudinal studies have 
shown that SN hyperechogenicty does not differ in 
size during the course of PD [3, 8]. Finally the pro-
spective study demonstrated a highly increased risk 
for PD in healthy elderly individuals with SN hypere-
chogenicity presence [10].
Hence, most of experts in this field treat this TCS 
phenomenon as a marker of PD, which can be helpful 
not only in early diagnosis but also in the predisposition 
assessment of this disorder [6]. There are several stu- 
dies, which revealed the extent of SN hyperechogenici-
ty in asymptomatic carriers of mutations of well-known 
PD-causing genes, as LRRK2 and PARK2 [12, 18].
However, there are 2 crucial points of criticism 
regarding SN area evaluation: the first one is a de-
pendence on the examiner’s experience. In our study 
intra-rater reliability in experienced neurosonogra-
pher was relatively good but inter-observer reliability 
(qualified vs. inexperienced sonographer in TCS) was 
moderate. This is consistent with previous reports that 
SN hyperechogenicity measurement reproducibility is 
high when performed by 1 experienced investigator 
[26, 27].
The second issue is the bias of the examiner who 
can notice evident extrapyramidal signs in patients 
with severe PD. In 1 recent interesting study sono- 
graphers were completely blinded: the examination 
room was completely darkened and the patients were 
veiled. Still the positive predictive value for PD was 
very high, i.e. 85.7% [24].
The basis of SN hyperechogenecity phenomenon is 
not clear enough. TCS of post-mortem brains and ani-
mal studies indicate that this abnormality may be related 
to iron deposition with formation of free radicals [7, 9]. 
There is also a hypothesis that it could be the 
result of microglial activation [5]. Further studies in 
this area are needed. 
There is one important limitation of our work: 
it was carried on well-defined PD patients; we did 
not include any subjects with atypical Parkinsonian 
syndrome. However, the aim of the study was to 
estimate the presence of SN hyperechogenicity in 
clear condition in homogenous population of Polish 
patients. The role of SN abnormalities assessment 
in differential diagnostics might be analysed in our 
following studies.  
CONCLUSIONS
In conclusion, SN hyperechogenicity as measured 
by TCS is a distinguishing feature related to PD that 
can improve the routine practice of movement dis-
orders specialists.
Table 1. Demographic and clinical data of Parkinson’s disease 
patients
SN  
£ 0.19 cm2
SN  
> 0.19 cm2
P
Number of patients 17 78 NA
Age [years] 59 ± 9 62 ±11 0.5
Sex (male/female) 8/9 49/29 0.3
Disease duration [years] 7 ± 4 7 ± 2 0.5
MDS-UPDRS score 28.5 ± 12 38.5 ± 20 0.2
Hoehn and Yahr stage 2.5 ± 1 2 ± 0,5 0.2
Tremor dominant type 2 14
0.4Akinetic-rigid type 3 26
Mixed type 10 40
271
W. Ambrosius et al., SN hyperechogenicity in Parkinson’s disease
REfERENCES
1. Ambrosius W, Kozubski W (2010) Transcranial sonography 
in diagnosis of movement disorders. Neurol Neurochir 
Pol, 44: 574–579.
2. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K 
(1995) Degeneration of substantia nigra in chronic 
Parkinson’s disease visualized by transcranial color-coded 
real-time sonography. Neurology, 45: 182–184.
3. Behnke S, Runkel A, Kassar AS, Ortmann M, Guidez D, 
Dillmann U, Fassbender K, Spiegel J (2013) Long-term co-
urse of substantia nigra hyperechogenicity in Parkinson’s 
disease. Mov Disord, 28: 455–459.
4. Berg D, Becker G, Zeiler B, Tucha O, Hofmann E, Preier M, 
Benz P, Jost W, Reiners K, Lange KW (1999) Vulnerability 
of the nigrostriatal system as detected by transcranial 
ultrasound. Neurology, 53: 1026–1031.
5. Berg D, Godau J, Riederer P, Gerlach M, Arzberger T (2010) 
Microglia activation is related to substantia nigra echoge-
nicity. J Neural Transm, 117: 1287–1292. 
6. Berg D, Godau J, Walter U (2008) Transcranial sonography 
in movement disorders. Lancet Neurol, 7: 1044–1055.
7. Berg D, Grote C, Rausch WD, Maeurer M, Wesemann W, 
Riederer P, Becker G (1999) Iron accumulation in the sub-
stantia nigra in rats visualized by ultrasound. Ultrasound 
Med Biol, 25: 901–904.
8. Berg D, Merz B, Reiners K, Naumann M, Becker G (2005) 
Five-year follow-up study of hyperechogenicity of the 
substantia nigra in Parkinson’s disease. Mov Disord, 20: 
383–385.
9. Berg D, Roggendorf W, Schröder U, Klein R, Tatschner T, 
Benz P, Tucha O, Preier M, Lange KW, Reiners K, Gerlach M, 
Becke G (2002) Echogenicity of the substantia nigra: 
association with increased iron content and marker for 
susceptibility to nigrostriatal injury. Arch  Neurol, 59: 
999–1005.
10. Berg D, Seppi K, Behnke S, Liepelt I, Schweitzer K, Stockner H, 
Wollenweber F, Gaenslen A, Mahlknecht P, Spiegel J, 
Godau J, Huber H, Srulijes K, Kiechl S, Bentele M, Gasperi A, 
Schubert T, Hiry T, Probst M, Schneider V, Klenk J, Sawires M, 
Willeit J, Maetzler W, Fassbender K, Gasser T, Poewe W 
(2011) Enlarged substantia nigra hyperechogenicity and 
risk for Parkinson disease: a 37-month 3-center study of 
1847 older persons. Arch Neurol, 68: 932–937.
11. Berg D, Siefker C, Becker G (2001) Echogenicity of the 
substantia nigra in Parkinson’s disease and its relation to 
clinical findings. J Neurol, 248: 684–689.
12. Brüggemann N, Hagenah J, Stanley K, Klein Ch, Wang C, 
Raymond D, Ozelius L, Bressman S, Saunders-Pullman R 
(2011) Substantia nigra hyperechogenicity with LRRK2 
G2019S mutations. Mov Disord, 26: 885–888.
13. Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, 
Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) 
Prevalence and incidence of Parkinson’s disease in Europe. 
Eur Neuropsychopharmacol, 15: 473–490.
14. Doepp F, Plotkin M, Siegel L, Kivi A, Gruber D, Lobsien E, 
Kupsch A,  Schreiber SJ (2008) Brain parenchyma sono-
graphy and 123I-FP-CIT SPECT in Parkinson’s disease and 
essential tremor. Mov Disord, 23: 405–410.
15. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, 
Peterson BJ, Ahlskog JE, Schaid DJ, Rocca W (2002) Risk 
tables for parkinsonism and Parkinson’s disease. J Clin 
Epidemiol, 55: 25–31.
16. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for 
Parkinson disease. Arch Neurol, 56: 33–39.
17. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, 
Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Hollo-
way R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, 
LeWitt PA, Nyenhuis D, Olanow W, Rascol O, Schrag A, 
Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disor-
der Society-sponsored revision of the Unified Parkinson’s 
Disease Rating Scale (MDS-UPDRS): Process, format, and 
clinimetric testing plan. Mov Disord, 22: 41–47.
18. Hagenah JM, König IR, Becker B, Hilker R, Kasten M, 
Hedrich K, Pramstaller PP, Klein C, Seidel G. (2007) Sub-
stantia nigra hyperechogenicity correlates with clinical 
status and number of Parkin mutated alleles. J Neurol, 
254: 1407–1013.
19. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progres-
sion, and mortality. Neurology, 17: 427–442.
20. Huang YW, Jeng JS, Tsai CF, Chen LL, Wu RM (2007) Trans-
cranial imaging of substantia nigra hyperechogenicity in 
a Taiwanese cohort of Parkinson’s disease. Mov Disord, 
22: 550–555.
21. Kolevski G, Petrov I, Petrova V (2007) Transcranial sono-
graphy in the evaluation of Parkinson disease. J Ultrasound 
Med, 26: 509–512.
22. Korchounov A, Schipper HI, Preobrazhenskaya IS, Kessler KR, 
Yakhno NN (2004) Differences in age at onset and fa-
milial aggregation between clinical types of idiopathic 
Parkinson’s disease. Mov Disord, 19: 1059–1064.
23. Lo RY, Tanner CM (2013) Epidemiology. In: Pahwa R, Lyons KE 
eds. Handbook of Parkinson’s disease. 5 Ed. CRC Press, 
London, pp. 24–39.
24. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D (2006) 
Predictive value of transcranial sonography in the diag-
nosis of Parkinson’s disease. Mov Disord, 21: 1763–1765.
25. Ressner P, Skoloudík D, Hlustík P, Kanovský P (2007) 
Hyperechogenicity of the substantia nigra in Parkinson’s 
disease. J Neuroimaging, 17: 164–167.
26. Skoloudík D, Fadrná T, Bártová P, Langová K, Ressner P, 
Zapletalová O, Hlustík P, Herzig R, Kannovský P 
(2007) Reproducibility of sonographic measurement 
of the substantia nigra. Ultrasound Med Biol, 33: 
1347–1352.
27. Van De Loo S, Walter U, Behnke S, Hagenah J, Lorenz M, 
Sitzer M, Hilker R, Berg D (2010) Reproducibility and 
diagnostic accuracy of substantia nigra sonography for 
the diagnosis of Parkinson’s disease. J Neurol Neurosurg 
Psychiatry, 81: 1087–1092.
28. Vlaar AM, De Nijs T, Van Kroonenburgh MJ. Mess WH, 
Winogrodzka A, Tromp SC, Weber WE (2008) The 
predictive value of transcranial duplex sonography 
for the clinical diagnosis in undiagnosed parkinso-
nian syndromes: comparison with SPECT scans. BMC 
Neurology, 8: 42.
29. Walter U (2012) Transcranial sonography of the cerebral 
parenchyma: Update on clinically relevant applications. 
Perspectives in Medicine, 1: 334–343.
30. Walter U, Behnke S, Eyding J, Niehaus L, Postert T, Seidel G, 
Berg D (2007) Transcranial brain parenchyma sonography 
in movement disorders: state of the art. Ultrasound Med 
Biol, 33: 15–25.
31. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R (2007) 
Transcranial brain sonography findings in clinical subgroups 
of idiopathic Parkinson’s disease. Mov Disord, 22: 48–54.
32. Walter U, Wittstock M, Benecke R,Dressler D (2002) Sub-
stantia nigra echogenicity is normal in non-extrapyramidal 
cerebral disorders but increased in Parkinson’s disease. 
J Neural Transm, 192: 191–196.
